Core Laboratories (NYSE:CLB – Get Free Report) issued an update on its second quarter earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.19-0.23 for the period, compared to the consensus estimate of $0.21. The company issued revenue guidance of $130-136 million, compared to the consensus revenue estimate of $129.49 million.
Core Laboratories Price Performance
CLB traded down $0.46 during trading on Wednesday, reaching $16.53. The stock had a trading volume of 412,649 shares, compared to its average volume of 464,965. The firm has a market capitalization of $774.60 million, a price-to-earnings ratio of 19.63, a price-to-earnings-growth ratio of 0.96 and a beta of 2.40. The company has a quick ratio of 1.72, a current ratio of 2.53 and a debt-to-equity ratio of 0.71. Core Laboratories has a 1-year low of $13.82 and a 1-year high of $27.94. The stock has a 50 day moving average of $16.20 and a two-hundred day moving average of $17.68.
Core Laboratories (NYSE:CLB – Get Free Report) last announced its earnings results on Wednesday, January 31st. The oil and gas company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.01). Core Laboratories had a net margin of 8.03% and a return on equity of 15.19%. The firm had revenue of $128.21 million for the quarter, compared to analyst estimates of $127.80 million. During the same period last year, the firm earned $0.23 earnings per share. As a group, equities analysts anticipate that Core Laboratories will post 0.8 EPS for the current fiscal year.
Core Laboratories Announces Dividend
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on CLB shares. Bank of America dropped their price target on shares of Core Laboratories from $17.00 to $16.00 and set an underperform rating for the company in a research report on Monday, April 15th. StockNews.com raised shares of Core Laboratories from a sell rating to a hold rating in a report on Saturday, January 20th. Finally, Stifel Nicolaus lowered their price target on shares of Core Laboratories from $21.00 to $17.00 and set a hold rating for the company in a report on Monday, February 5th. Two analysts have rated the stock with a sell rating and three have given a hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Hold and an average target price of $18.50.
View Our Latest Research Report on CLB
About Core Laboratories
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Featured Articles
- Five stocks we like better than Core Laboratories
- How to Calculate Return on Investment (ROI)
- High-Yield Texas Instruments Could Hit New Highs Soon
- Energy and Oil Stocks Explained
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.